{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-040137","form_type":"8-K","ticker":"CSBR","cik":"0000771856","company_name":"CHAMPIONS ONCOLOGY, INC.","filed_at":"2024-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.825235+00:00","generated_at":"2026-05-31T05:31:38.645476+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Champions Oncology Q1 revenue $14.1M, net income $1.3M, adjusted EBITDA $2.0M","bullets":["Revenue rose 12% YoY to $14.1M; net income of $1.3M vs. loss of $2.6M a year ago.","Adjusted EBITDA of $2.0M vs. loss of $1.7M; margin improved to 49.7% from 38.8%.","Total costs and expenses fell 15.8% to $12.7M; cash $2.9M with zero debt.","CEO cites cost cuts and leaner operations; expects some volatility but sustained EBITDA profitability.","Conference call scheduled for Sept. 11 at 4:30 p.m. EDT."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-040137","json":"https://secwatch.observer/filing/0001628280-24-040137.json","markdown":"https://secwatch.observer/filing/0001628280-24-040137.md","text":"https://secwatch.observer/filing/0001628280-24-040137.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/771856/000162828024040137/0001628280-24-040137-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/771856/000162828024040137/csbr-20240911.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:31:38.645476+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}